Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2008

TORREYPINES THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   000-25571   86-0883978
(State or Other
Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

11085 North Torrey Pines Road, Suite 300, La Jolla, CA   92037
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 623-5665

      

 

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01. Other Events

On October 1, 2008, TorreyPines Therapeutics, Inc. issued a press release announcing that it held a successful End-of-Phase II meeting for tezampanel with the U.S. Food and Drug Administration on September 29, 2008. A copy of the press release is attached as Exhibit 99.1.

 

Item 9.01. Financial Statements and Exhibits

 

  (d) The following exhibit is furnished herewith:

 

99.1    Press release dated October 1, 2008

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    TORREYPINES THERAPEUTICS, INC.
Date: October 1, 2008     By:   /s/ Craig Johnson
    Name:    Craig Johnson
    Title:   Vice President, Finance and
      Chief Financial Officer

 

3


INDEX TO EXHIBITS

 

Exhibit
Number

  

Description

99.1    Press release dated October 1, 2008

 

4